Physician profile
Meng Chen
NPI 1497190714
$7,873.17
in general payments reported to CMS, 2019-2025
16 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,481 · 2020: $208 · 2021: $253 · 2022: $97.26 · 2023: $1,440 · 2024: $130 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Food and Beverage | $533.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $5,051.01 | 2019 | |
| Glaxosmithkline, LLC. | $1,502.60 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $377.16 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $256.25 | 2019-2025 | |
| Genentech USA, INC. | $215.47 | 2019-2024 | Xolair |
| Coloplast Corp | $118.66 | 2023 | Titan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.28 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $56.65 | 2019 | |
| Arcutis Biotherapeutics, INC. | $41.79 | 2024-2025 | Zoryve |
| Optinose US, INC. | $40.43 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $33.81 | 2019-2023 | Breztri |
| Pfizer INC. | $23.86 | 2019 | |
| Kaleo, INC. | $18.41 | 2019 | |
| Alk-Abello, INC | $18.03 | 2019 | |
| Shire North American Group INC | $16.76 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meng Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.